NCT05400317 A Study to Evaluate the Efficacy and Safety of AD-218
| NCT ID | NCT05400317 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Addpharma Inc. |
| Condition | Mixed Dyslipidemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 520 participants |
| Start Date | 2022-07-27 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 520 participants in total. It began in 2022-07-27 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of AD-218
Eligibility Criteria
Inclusion Criteria: * A man or woman over 19 years old. * Sign on ICF prior to study participation Exclusion Criteria: * History of Fibromyalgia, Myopathy etc (CK ≥ 2 X ULN) * Other exclusions applied
Contact & Investigator
Kyu Chang Won, M.D., Ph.D
PRINCIPAL INVESTIGATOR
Yeungnam University Hospital
Frequently Asked Questions
Who can join the NCT05400317 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Mixed Dyslipidemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05400317 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 520 participants.
Is NCT05400317 currently recruiting?
Yes, NCT05400317 is actively recruiting participants. Contact the research team at sryoon@addpharma.co.kr for enrollment information.
Where is the NCT05400317 trial being conducted?
This trial is being conducted at Daegu, South Korea.
Who is sponsoring the NCT05400317 clinical trial?
NCT05400317 is sponsored by Addpharma Inc.. The principal investigator is Kyu Chang Won, M.D., Ph.D at Yeungnam University Hospital. The trial plans to enroll 520 participants.